Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New injection aims to tame autoimmune attacks

NCT ID NCT07408336

First seen Feb 24, 2026 · Last updated Jun 18, 2026 · Updated 19 times

Summary

This early-stage study tests a new injection called AFN50 in 18 adults with autoimmune diseases like lupus. The main goal is to check safety and see how the body reacts, including changes in immune cells. Participants must have active disease despite standard treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • First Affiliated Hospital of Anhui Medical University

    RECRUITING

    Hefei, Anhui, 230001, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

The condition(s) this trial relates to.

autoimmune disease systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.